Abstract：Objective：To conduct a retrospective analysis of the clinical effect and safety of demethylation stratification therapy combined with compound Junzi tang for senile acute myeloid leukemia(AML). Methods：A total of 78 cases of senile AML patients were divided into the observation group and the control group according to their treatment intentions，40 and 38 cases in each group respectively. The control group was treated with standard dose of decitabine and CAG plan for demethylation. The observation group was treated with demethylation stratification therapy with different doses of decitabine，considering their ages，complications and physical conditions，and combined with compound Junzi tang. Both groups were treated for at least two courses，28±4 days being a course. The short-term curative effects，curative effect of Chinese medicine syndromes， long- term survival and treatment safety in the two groups were evaluated. Results： After two courses of treatment，the total remission rate of short-term curative effect and total effective rate of Chinese medicine syndromes in the observation group were higher than those in the control group(P＜0.05). The average survival time in the observation group was longer than that in the control group(P＜0.05). The incidence of adverse reactions in the observation group was lower than that in the control group(P＜0.05). Conclusion： Demethylation stratification therapy combined with compound Junzi tang can increase the tolerance of demethylation therapy of the senile AML patients， reduce adverse reactions，and prolong the overall survival and recurrence-free survival.